Neumora Therapeutics Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -74.98%. The profit margin, also known as the revenue ratio or gross profit ...

Investment analysts at William Blair issued their FY2029 earnings per share estimates for shares of Neumora Therapeutics in a ...

Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) saw some unusual options trading on Monday. Stock traders acquired ...

Neumora Therapeutics Inc (NMRA) stock saw a modest uptick, ending the day at $2.17 which represents a slight increase of $0.20 or 10.15% from the prior close of $1.97. The stock opened at $2.23 and ...

BofA analyst Geoff Meacham lowered the firm’s price target on Neumora Therapeutics (NMRA) to $7 from $22 and keeps a Buy rating on the shares.

Neumora Therapeutics announced that its antidepressant candidate, navacaprant, did not meet the primary endpoint in a Phase 3 study for major depressive disorder.

Meanwhile, increased rates of cancer in the under 50 crowd may be caused by gut issues; certain foods, including licorice, may help covid patients; Neumora Therapeutics depression treatment fails ...

The KOASTAL-1 study enrolled 383 adult patients with MDD. Navacaprant was shown to be safe and generally well-tolerated with ...

Shares of Neumora Therapeutics NMRA lost more than 80% on Thursday after reporting the failure of its lead pipeline drug, ...

Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 ...

Good morning, Boston. Here are the five things you need to know in local business news to start your post-holiday Friday.

China's Health Commission aims to enhance mental health services by 2027, focusing on children and adolescents. Eli Lilly ...